Forte Biosciences (FBRX) Free Cash Flow (2016 - 2026)
Forte Biosciences (FBRX) posted quarterly Free Cash Flow of -$18.8 million for Q1 2026, down 80.49% year-over-year from -$96.4 million in Q1 2025, and down 14.05% quarter-over-quarter from -$16.5 million in Q4 2025.
Forte Biosciences (FBRX) Free Cash Flow (2016 - 2026) Analysis & Trends
Forte Biosciences (FBRX) has reported Free Cash Flow for 11 consecutive years, with -$18.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 80.49% year-over-year to -$18.8 million; the TTM figure through Mar 2026 stood at -$59.4 million (down 72.05% YoY), while the FY2025 annual figure was -$51.0 million, down 65.73% from the prior year.
- Free Cash Flow slipped to -$18.8 million in Q1 2026 per FBRX's latest filing, from -$16.5 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$1.4 million in Q2 2022 and bottomed at -$18.8 million in Q1 2026.
- Historically, Free Cash Flow has averaged -$8.1 million across 5 years, with a median of -$8.1 million in 2024.
- Annual changes were most pronounced in 2022 — Free Cash Flow surged 65.03% — and 2023, when it slumped 369.02%.
- Forte Biosciences' Free Cash Flow stood at -$2.9 million in 2022, then plunged by 210.61% to -$9.0 million in 2023, then slipped by 11.73% to -$10.0 million in 2024, then tumbled by 64.18% to -$16.5 million in 2025, then dropped by 14.05% to -$18.8 million in 2026.
- Business Quant data shows FBRX's Free Cash Flow at -$18.8 million in Q1 2026, -$16.5 million in Q4 2025, and -$14.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Forte Biosciences | 1.63 Bn | 1.28 Bn | - | -22.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -22.70 Mn |
| Jun 30, 2026 | -22.70 Mn |
| Mar 31, 2026 | -18.80 Mn |
| Mar 31, 2026 | -18.80 Mn |
| Dec 31, 2025 | -16.48 Mn |
| Dec 31, 2025 | -16.48 Mn |
| Sep 30, 2025 | -14.06 Mn |
| Sep 30, 2025 | -14.06 Mn |
| Jun 30, 2025 | -10.06 Mn |
| Jun 30, 2025 | -10.06 Mn |
| Mar 31, 2025 | -10.42 Mn |
| Mar 31, 2025 | -10.42 Mn |
| Dec 31, 2024 | -10.04 Mn |
| Dec 31, 2024 | -10.04 Mn |
| Sep 30, 2024 | -8.13 Mn |
| Sep 30, 2024 | -8.13 Mn |
| Jun 30, 2024 | -5.94 Mn |
| Jun 30, 2024 | -5.94 Mn |
| Mar 31, 2024 | -6.67 Mn |
| Mar 31, 2024 | -6.67 Mn |